Almirall SA
https://www.almirall.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Almirall SA
Ambitious Almirall Lays Out Ebglyss Launch Plans
The Spanish firm is all set to launch its atopic dermatitis drug in Germany later this month and is hopeful of a smooth reimbursement path across Europe.
Almirall Enlists Absci’s AI Expertise For Dermatology Drug Discovery
Deal Snapshot: In Almirall’s first de novo artificial intelligence drug discovery and development collaboration, the company will pay up to $650m to work with Absci on two dermatology candidates.
All Systems Go At Almirall To Enter Tough Atopic Dermatitis Market With Ebglyss
Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.
Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Almirall S.A.
- Almirall LLC
- Aqua Pharmaceuticals
- Taurus Pharma GmbH
- Polichem S.A.
- Polichem S.r.l.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice